Khosla Ventures

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Noetik is an AI-native biotechnology company focused on the discovery and development of cancer immunotherapies. Utilizing advanced machine learning techniques, Noetik's platform identifies new therapeutic targets and designs innovative treatments. By leveraging self-supervised learning and integrating human multimodal data, the company aims to enhance the effectiveness and personalization of cancer therapies, thereby improving patient outcomes in oncology.

Q Bio, founded in 2015 by Jeffrey Kaditz, Dr. Michael Snyder, and Dr. Garry Choy, operates a clinical digital twin platform aimed at assessing patients' medical histories to identify immediate and future health risks. Based in San Carlos, California, the company utilizes whole-body scans to create a digital twin of each patient's physical body, quantifying and digitizing health data. By leveraging simulated human physiology and machine learning, Q Bio's platform can predict potential health risks, enabling healthcare professionals to provide proactive treatment. The interdisciplinary team at Q Bio comprises experts in applied mathematics, computational physics, electrical engineering, genetics, and radiology, supported by prominent venture capital firms.

Sword Health is a digital health company focused on revolutionizing physical rehabilitation through its advanced artificial intelligence care platform. The company aims to alleviate pain for billions of people by providing a unique solution that combines the expertise of physical therapy professionals with an interactive AI experience. This platform enables patients to access customized rehabilitation exercises from their homes, allowing them to receive supervised care anytime and anywhere. Sword Health's approach not only enhances patient independence but also offers valuable data to clinical teams and decision-makers, ultimately improving clinical and cost-saving outcomes in the field of physical therapy.

Rad AI, Inc. is a company based in Berkeley, California, that specializes in developing an artificial intelligence platform designed to automate report generation for radiologists. Founded in 2018, Rad AI's solution streamlines the radiology workflow by automating repetitive tasks, thereby enhancing efficiency and accuracy while addressing issues of clinician burnout. The platform utilizes AI to generate report impressions, allowing radiologists to dictate findings using voice recognition technology, identify errors, and customize recommendations. By integrating smoothly with existing workflows, Rad AI aims to improve patient care and support radiologists in delivering accurate and timely reports.

Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing therapies that target senescent cells responsible for various age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of innovative therapeutic candidates. These candidates include novel small molecules designed to selectively address senescent cells, which contribute to the progression of several chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises experienced professionals from the fields of chemistry, technology, and life sciences, bringing a wealth of knowledge in drug development and commercialization.

Nabla Bio operates an autoreverse platform that facilitates the rapid discovery of novel protein variants with unique properties. By leveraging insights gained from billions of natural proteins, the company engineers these enhanced proteins for both medical and industrial applications. Through extensive experimentation, Nabla Bio develops new medicines and improves nutritional products, allowing clients to conduct complex measurements of protein function and implement innovative solutions in various fields.

Loyal is a biotechnology company focused on developing veterinary pharmaceuticals aimed at extending the lifespan and improving the health span of dogs. By creating medications that target the aging process, Loyal seeks to delay or prevent the onset of age-related diseases, including cancer, heart disease, and metabolic disorders. The company's innovative approach involves quantifying and regulating the biological processes associated with aging, which helps to mitigate the severity of these ailments. Through its research and product development, Loyal strives to ensure that dogs can enjoy longer, healthier lives, ultimately benefiting both pets and their owners.

CureSkin is a Bengaluru-based company founded in 2016 that specializes in AI-powered mobile applications for dermatological care. The app utilizes computer vision technology to analyze user-uploaded photos, identifying various skin issues such as acne, dark spots, scars, and pigmentation. Based on the analysis, CureSkin recommends personalized treatment plans, skincare products, and connects users with dermatologists for follow-up consultations. By offering these services, CureSkin aims to provide accessible and effective skin health solutions, particularly for individuals who may not have easy access to trained professionals.

Siolta Therapeutics, Inc. is a clinical-stage biotech company based in San Francisco, California, focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016, the company utilizes its expertise in the developing gut microbiome to promote immune tolerance. Siolta's platform includes the development of pharmaceutical-grade anaerobic organisms and microbiome-based diagnostics that support precision medicine. By leveraging insights from human microbiome studies, Siolta Therapeutics aims to create targeted microbial therapeutics that address the underlying causes of inflammatory diseases, enabling a new approach to prevention and treatment.

Limbic is a London-based company that specializes in mental healthcare technology. Founded in 2017, it develops a software development kit (SDK) that leverages machine learning to analyze heart rate data collected from wearable devices like the Apple Watch, allowing for the assessment of users' emotional states. Limbic also offers psychological therapies for adults, focusing on improving mental health through innovative solutions. Its platform supports healthcare professionals by providing tools for stress detection and facilitating clinical assessments, thereby enhancing the efficacy of psychological therapy. By combining AI technology with wearable devices, Limbic aims to address the growing challenges in mental health care and improve patient outcomes.

Moonwalk Biosciences is a genomic medicine startup focused on developing precision epigenetic therapeutics. The company is creating a profiling and engineering technology platform that leverages advanced artificial intelligence to deliver an in-depth understanding of the epigenome in both health and disease. This innovative approach allows healthcare providers to explore new avenues for therapy discovery and facilitates the reprogramming of cells to restore their healthy state. By integrating AI-driven insights, Moonwalk Biosciences aims to transform the landscape of therapeutic development and improve patient outcomes.

Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics. It has dedicated experts focused on the investigation and advancement of next-generation therapies. It aims to help patients with chronic diseases, starting with Type 1 diabetes. It was founded in 2016 and is headquartered in San Francisco, California.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies. Its platform cultures the most realistic human tissues ever lab-grown to answer deep questions about human health.

Forward is a startup redesigning the way healthcare is delivered using all the technologies healthcare has neglected such as sensors, mobile, and AI. Forward was founded in January 2016 by former executives and engineering leaders from Google and Uber and led by serial entrepreneur Adrian Aoun. Forward is funded by investors and entrepreneurs including First Round Capital, Eric Schmidt (Google/Alphabet chairman), Marc Benioff (Salesforce founder), Joe Lonsdale (Palantir founder), Joshua Kushner (Oscar co-founder), and Garrett Camp (Uber co-founder).

CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells.

Rejuvenation Technologies Inc. is a biotechnology company based in Mountain View, California, focused on developing nucleoside-modified telomerase reverse transcriptase messenger RNA to extend telomeres and promote human health. The company's innovative approach involves delivering a telomere extender that encodes telomerase reverse transcriptase, which transiently boosts telomerase activity in cells. This technology aims to enhance the proliferative capacity of cells, potentially addressing age-related diseases and conditions in various medical fields, including hepatic, pulmonary, and immunology. Additionally, Rejuvenation Technologies offers a range of cell therapies that encompass tissue engineering, cell transplants, skin grafts, immunotherapy, and regenerative medicine. Established in 2016, the company is dedicated to advancing solutions in regenerative health.

SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed. The company provides an injectable biodegradable hydrogel that allows for the prolonged, localized release of most cancer immunotherapy on the website of surgical tumor resection by focusing the dose at the right place and right time.

Helping people with chronic conditions mitigate their symptoms.

Tachyon Therapeutics is a biotechnology company focused on developing innovative therapeutics for cancer treatment. The firm specializes in creating selective compounds that target significant drug targets within cancer biology, employing advanced methodologies in molecular cancer biology, epigenetics, and cancer stem cell biology. Currently, Tachyon is conducting Phase 1 clinical trials to evaluate the safety, pharmacokinetics, and anti-tumor effectiveness of its lead compound, TACH101, in patients with advanced cancer. The company's research and development efforts aim to unlock new pathways for treating challenging cancer types, ensuring that its programs are advanced in a timely and scientifically rigorous manner.

IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.

Bionaut Labs, Inc. is a biotechnology company based in Palo Alto, California, founded in 2016. The company specializes in developing a novel intra-tissue navigation platform utilizing Bionaut nano/micro robots that operate within the body. This innovative technology enables precise anatomical targeting for the treatment of central nervous system disorders, offering a new approach to precision medicine. By employing remote-controlled micro-robots, Bionaut Labs enhances the development of therapeutics, making advanced technologies like gene therapy and CRISPR-Cas9 feasible in challenging clinical scenarios. The Bionaut platform allows medical professionals to access any anatomic location within the body, facilitating the automation of complex procedures while eliminating the need for external incisions, thereby improving patient outcomes for those with limited treatment options.

SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed. The company provides an injectable biodegradable hydrogel that allows for the prolonged, localized release of most cancer immunotherapy on the website of surgical tumor resection by focusing the dose at the right place and right time.

Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines to improve outcomes for liver transplant patients. Established in 2019 and headquartered in Headington, United Kingdom, the company specializes in rejuvenating donor livers before transplantation, ensuring that more patients in need of a new liver receive one. Utilizing advanced genomic techniques, Ochre Bio identifies and targets over-active genes that contribute to liver diseases. The company tests its novel RNA-based therapies on discarded donor livers kept alive outside the body, allowing for direct evaluation of treatment efficacy. With roots in over 15 years of liver genomics research, Ochre Bio aims to address liver-related conditions and enhance the availability of healthy livers for transplantation.

Vitara Biomedical develops a therapeutic platform to support premature infants. It offers natural physiological processes and hopes to transform neonatal care for newborns and their families into a lifetime of possibilities.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

By using data, technology, and high quality medical expertise, we aim to deliver an empathetic people-centric healthcare experience that helps people live longer.

Turn.bio is a biotechnology company focused on developing drugs aimed at reversing aging and age-related diseases. Leveraging its patented mRNA platform technology, known as ERA, the company addresses the effects of aging on the epigenome, thereby restoring optimal gene expression. Turn.bio’s innovative approach enables the body to heal itself by instructing specific cells to combat diseases or repair damaged tissues. The company targets a range of medical indications, including immune-related diseases such as cancer, dermatological conditions, ophthalmology, osteoarthritis, and issues related to the muscular system. Through its advanced delivery platform, eTurna, Turn.bio seeks to enhance the effectiveness of nucleic acid therapeutics in promoting health and longevity.

Cellino is focused on creating an automated biomanufacturing system for personalized cell therapies, with the aim of making these treatments widely accessible. The company leverages an AI-guided laser editing platform that employs image-guided machine learning and robotics to generate autologous induced pluripotent stem cells (iPSCs) at scale. This innovative approach is designed to facilitate the development of potentially curative therapies for chronic degenerative diseases, such as vision loss and Parkinson's disease. By streamlining the process of cell therapy production, Cellino aims to enhance the availability of life-saving medicines for patients around the world.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

NextVivo is a biotechnology company focused on advancing drug development through its innovative immune organoid technology platform. This platform generates human cell and antibody candidate therapies by harnessing the body's immune system. NextVivo's organoids are miniature 3D cell cultures designed to replicate the composition, structure, and function of human tissues, allowing for a realistic modeling of the humoral and cellular immune responses outside the body. This technology enables the testing of pre-clinical candidates on ex vivo human tissue models, facilitating the identification of the most effective therapies for clinical development. The company's mission is to accelerate the creation of safer and more effective treatments by utilizing immune-competent, human-derived models.

Nabla Bio operates an autoreverse platform that facilitates the rapid discovery of novel protein variants with unique properties. By leveraging insights gained from billions of natural proteins, the company engineers these enhanced proteins for both medical and industrial applications. Through extensive experimentation, Nabla Bio develops new medicines and improves nutritional products, allowing clients to conduct complex measurements of protein function and implement innovative solutions in various fields.

Sword Health is a digital health company focused on revolutionizing physical rehabilitation through its advanced artificial intelligence care platform. The company aims to alleviate pain for billions of people by providing a unique solution that combines the expertise of physical therapy professionals with an interactive AI experience. This platform enables patients to access customized rehabilitation exercises from their homes, allowing them to receive supervised care anytime and anywhere. Sword Health's approach not only enhances patient independence but also offers valuable data to clinical teams and decision-makers, ultimately improving clinical and cost-saving outcomes in the field of physical therapy.

Pearl Bio is a synthetic biology company focused on advancing the field of biologics and biomaterials. It has developed a platform that incorporates genome engineering, ribosome engineering, and biomanufacturing techniques. This platform allows for the creation of innovative biomaterials and smart biologics, enabling researchers to enhance their understanding of gene function. Pearl Bio's work aims to facilitate the development of products and processes that can be utilized at a commercial scale, ultimately providing new avenues for treating genetic and acquired diseases.

Lightship is a company founded in 2018 that focuses on enhancing access, choice, and equity in clinical trials through decentralized and hybrid clinical services. By leveraging innovations in digital health and technology, Lightship aims to transform the clinical research landscape by improving patient experiences, retention, and trial diversity. The company moves beyond traditional research centers to make clinical studies more accessible, allowing medical research organizations to overcome the barriers and inefficiencies associated with conventional clinical trial models. Its mission centers on placing patients at the forefront, ensuring that clinical research is designed to meet the needs of diverse populations globally.

By using data, technology, and high quality medical expertise, we aim to deliver an empathetic people-centric healthcare experience that helps people live longer.

Loyal is a biotechnology company focused on developing veterinary pharmaceuticals aimed at extending the lifespan and improving the health span of dogs. By creating medications that target the aging process, Loyal seeks to delay or prevent the onset of age-related diseases, including cancer, heart disease, and metabolic disorders. The company's innovative approach involves quantifying and regulating the biological processes associated with aging, which helps to mitigate the severity of these ailments. Through its research and product development, Loyal strives to ensure that dogs can enjoy longer, healthier lives, ultimately benefiting both pets and their owners.

House Rx is a health technology platform focused on improving affordability and patient access to specialty medications.

Karma Biotechnologies, Inc. is a Los Angeles-based startup focused on developing therapies for autoimmune diseases, allergies, and food sensitivities. Founded in 2019, the company offers Xavines, a precision immunotherapy platform designed to address the critical need for antigen-specific therapies that target only the rogue immune cells responsible for these conditions. Unlike traditional treatments that rely on general immune suppression, Karma Biotechnologies aims to create tolerogenic immunotherapies that promote antigen-specific immune tolerance in vivo. By leveraging its expertise in immunology and lipid nanoparticle engineering, the company seeks to provide innovative solutions that enhance the treatment landscape for autoimmune diseases and related disorders.

Known Medicine Inc., founded in 2020 and based in Salt Lake City, Utah, specializes in developing a custom organoid platform designed for tumor sensitivity testing. The company aims to enhance cancer treatment by conducting experiments on tumor responses to drugs in a controlled laboratory setting rather than within the patient’s body. Known Medicine's innovative approach involves breaking down tumor samples into microtumors, which are treated in specialized micro-environments using various methods to identify the most effective treatments. The platform utilizes machine learning-based sensitivity assays and integrates omics data to detect different cell types, including cancerous, stromal, and immune cells. This enables oncologists to analyze multiple microtumors, ultimately helping to determine optimal treatment strategies for individual patients.

Flow Neuroscience AB is a healthcare company based in Malmö, Sweden, focused on developing innovative treatment solutions for depression. Established in 2011, the company creates a wearable device that delivers transcranial direct current stimulation (tDCS) to the forehead, targeting the left frontal lobe, an area often associated with reduced activity in individuals suffering from major depressive disorder (MDD). This headset is complemented by a personalized mobile application designed to encourage users to adopt healthier daily routines, such as improved sleep patterns and increased physical activity. By combining brain stimulation with behavioral therapy, Flow Neuroscience aims to provide a medication-free treatment option that is accessible and affordable, challenging the traditional pharmaceutical approaches to depression. The company aspires to make these effective treatments widely available, moving beyond the confines of specialized clinics.

Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics. It has dedicated experts focused on the investigation and advancement of next-generation therapies. It aims to help patients with chronic diseases, starting with Type 1 diabetes. It was founded in 2016 and is headquartered in San Francisco, California.

Connie Health is a provider of medical advisory services focused on enhancing the experience of older Americans in navigating Medicare decision-making. The company utilizes an AI-driven technology platform, complemented by local Medicare experts, to assist individuals in maximizing their insurance benefits, optimizing prescription costs, and identifying healthcare providers in their vicinity. By offering personalized support, Connie Health empowers seniors to make informed healthcare choices, select the most appropriate healthcare plans, and effectively understand the benefits of their insurance coverage.

IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.

Sword Health is a digital health company focused on revolutionizing physical rehabilitation through its advanced artificial intelligence care platform. The company aims to alleviate pain for billions of people by providing a unique solution that combines the expertise of physical therapy professionals with an interactive AI experience. This platform enables patients to access customized rehabilitation exercises from their homes, allowing them to receive supervised care anytime and anywhere. Sword Health's approach not only enhances patient independence but also offers valuable data to clinical teams and decision-makers, ultimately improving clinical and cost-saving outcomes in the field of physical therapy.

Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines to improve outcomes for liver transplant patients. Established in 2019 and headquartered in Headington, United Kingdom, the company specializes in rejuvenating donor livers before transplantation, ensuring that more patients in need of a new liver receive one. Utilizing advanced genomic techniques, Ochre Bio identifies and targets over-active genes that contribute to liver diseases. The company tests its novel RNA-based therapies on discarded donor livers kept alive outside the body, allowing for direct evaluation of treatment efficacy. With roots in over 15 years of liver genomics research, Ochre Bio aims to address liver-related conditions and enhance the availability of healthy livers for transplantation.

Turn.bio is a biotechnology company focused on developing drugs aimed at reversing aging and age-related diseases. Leveraging its patented mRNA platform technology, known as ERA, the company addresses the effects of aging on the epigenome, thereby restoring optimal gene expression. Turn.bio’s innovative approach enables the body to heal itself by instructing specific cells to combat diseases or repair damaged tissues. The company targets a range of medical indications, including immune-related diseases such as cancer, dermatological conditions, ophthalmology, osteoarthritis, and issues related to the muscular system. Through its advanced delivery platform, eTurna, Turn.bio seeks to enhance the effectiveness of nucleic acid therapeutics in promoting health and longevity.

Pendulum Therapeutics Inc. is a microbiome-focused company based in San Francisco that specializes in developing medical probiotics and prebiotics aimed at managing chronic illnesses, particularly type 2 diabetes. The company's flagship product, Pendulum Glucose Control, was introduced in 2020 and has demonstrated effectiveness in lowering blood sugar spikes and reducing A1C levels, as evidenced by published clinical trials. Pendulum utilizes evidence-based microbiome science and DNA sequencing to create targeted interventions, allowing clinicians to identify specific microbiome markers for disease treatment. Founded in 2013, Pendulum holds 13 patents and has 42 pending, with significant backing from prominent investors. The company sells its products online, focusing on improving healthcare through innovative microbiome therapies.

Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.

Forward is a startup redesigning the way healthcare is delivered using all the technologies healthcare has neglected such as sensors, mobile, and AI. Forward was founded in January 2016 by former executives and engineering leaders from Google and Uber and led by serial entrepreneur Adrian Aoun. Forward is funded by investors and entrepreneurs including First Round Capital, Eric Schmidt (Google/Alphabet chairman), Marc Benioff (Salesforce founder), Joe Lonsdale (Palantir founder), Joshua Kushner (Oscar co-founder), and Garrett Camp (Uber co-founder).

Bionaut Labs, Inc. is a biotechnology company based in Palo Alto, California, founded in 2016. The company specializes in developing a novel intra-tissue navigation platform utilizing Bionaut nano/micro robots that operate within the body. This innovative technology enables precise anatomical targeting for the treatment of central nervous system disorders, offering a new approach to precision medicine. By employing remote-controlled micro-robots, Bionaut Labs enhances the development of therapeutics, making advanced technologies like gene therapy and CRISPR-Cas9 feasible in challenging clinical scenarios. The Bionaut platform allows medical professionals to access any anatomic location within the body, facilitating the automation of complex procedures while eliminating the need for external incisions, thereby improving patient outcomes for those with limited treatment options.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Cellino is focused on creating an automated biomanufacturing system for personalized cell therapies, with the aim of making these treatments widely accessible. The company leverages an AI-guided laser editing platform that employs image-guided machine learning and robotics to generate autologous induced pluripotent stem cells (iPSCs) at scale. This innovative approach is designed to facilitate the development of potentially curative therapies for chronic degenerative diseases, such as vision loss and Parkinson's disease. By streamlining the process of cell therapy production, Cellino aims to enhance the availability of life-saving medicines for patients around the world.

Sword Health is a digital health company focused on revolutionizing physical rehabilitation through its advanced artificial intelligence care platform. The company aims to alleviate pain for billions of people by providing a unique solution that combines the expertise of physical therapy professionals with an interactive AI experience. This platform enables patients to access customized rehabilitation exercises from their homes, allowing them to receive supervised care anytime and anywhere. Sword Health's approach not only enhances patient independence but also offers valuable data to clinical teams and decision-makers, ultimately improving clinical and cost-saving outcomes in the field of physical therapy.

Lumiata Inc. specializes in predictive health analytics tailored for risk-bearing organizations, including hospital networks and insurance carriers. Founded in 2013 and based in San Mateo, California, the company has developed a medical graph that organizes and analyzes diverse healthcare data, enabling real-time predictive analytics. Its flagship product, The Lumiata Risk Matrix, provides personalized predictions regarding individual health changes, supported by a chain of medical reasoning. By leveraging over 120 million patient records and proprietary clinical knowledge, Lumiata's machine learning tools empower healthcare providers and payers to enhance decision-making, manage costs, and improve patient care. The company serves a range of clients, including payers, population health organizations, and digital health companies, facilitating applications in underwriting and care management while prioritizing member privacy.

Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company leverages artificial intelligence to provide chat-based primary care services, aiming to make high-quality and affordable healthcare accessible to everyone, anytime. Curai Health's platform integrates clinicians with advanced AI and machine learning tools to create a learning healthcare system that enhances the efficiency and cost-effectiveness of medical care. By facilitating better communication between patients and healthcare professionals, the platform aids in accurate diagnosis and treatment. Curai Health offers its services directly to consumers and through partnerships with enterprises.

Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing therapies that target senescent cells responsible for various age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of innovative therapeutic candidates. These candidates include novel small molecules designed to selectively address senescent cells, which contribute to the progression of several chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises experienced professionals from the fields of chemistry, technology, and life sciences, bringing a wealth of knowledge in drug development and commercialization.

Siolta Therapeutics, Inc. is a clinical-stage biotech company based in San Francisco, California, focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016, the company utilizes its expertise in the developing gut microbiome to promote immune tolerance. Siolta's platform includes the development of pharmaceutical-grade anaerobic organisms and microbiome-based diagnostics that support precision medicine. By leveraging insights from human microbiome studies, Siolta Therapeutics aims to create targeted microbial therapeutics that address the underlying causes of inflammatory diseases, enabling a new approach to prevention and treatment.

Focal Medical, Inc. is a privately held biopharmaceutical company based in Cary, North Carolina, specializing in the development of innovative drug delivery systems for challenging cancers. The company focuses on creating targeted therapeutic products, with its lead offering designed to deliver gemcitabine directly to the pancreas through non-circulatory pathways, specifically targeting pancreatic cancer. This approach combines iontophoresis with an implantable delivery system, allowing for precise chemotherapy delivery that aims to enhance patient recovery. In addition to pancreatic cancer, Focal Medical is also exploring therapies for other solid tumors and genomic medicine products, underscoring its commitment to advancing treatment options for difficult-to-treat cancers.

IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.

HeartVista is a medical technology company that provides one-click diagnostic imaging. It brought in machine learning to make the scanning process faster, easier, and more consistent. Its platform leverages existing scanners and contains all of the mri tools needed for a comprehensive cardiac examination, with just one click.

Genalyte, Inc. is a clinical and diagnostic life science company that specializes in rapid diagnostic testing solutions for healthcare providers and researchers. Founded in 2007 and based in San Diego, California, Genalyte has developed the Maverick platform, which utilizes silicon photonics technology to directly measure the binding of biomolecules, such as antibodies and proteins, to silicon photonic biosensors. This innovative approach allows for the quick detection of various health conditions, including autoimmune diseases, cancer biomarkers, and infectious agents. The company’s systems enable mobile laboratories to deliver real-time diagnostics in under thirty minutes, enhancing the quality of care while optimizing resource use within the healthcare system.

Sword Health is a digital health company focused on revolutionizing physical rehabilitation through its advanced artificial intelligence care platform. The company aims to alleviate pain for billions of people by providing a unique solution that combines the expertise of physical therapy professionals with an interactive AI experience. This platform enables patients to access customized rehabilitation exercises from their homes, allowing them to receive supervised care anytime and anywhere. Sword Health's approach not only enhances patient independence but also offers valuable data to clinical teams and decision-makers, ultimately improving clinical and cost-saving outcomes in the field of physical therapy.

Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.

Q Bio, founded in 2015 by Jeffrey Kaditz, Dr. Michael Snyder, and Dr. Garry Choy, operates a clinical digital twin platform aimed at assessing patients' medical histories to identify immediate and future health risks. Based in San Carlos, California, the company utilizes whole-body scans to create a digital twin of each patient's physical body, quantifying and digitizing health data. By leveraging simulated human physiology and machine learning, Q Bio's platform can predict potential health risks, enabling healthcare professionals to provide proactive treatment. The interdisciplinary team at Q Bio comprises experts in applied mathematics, computational physics, electrical engineering, genetics, and radiology, supported by prominent venture capital firms.

Fountain Therapeutics, Inc. is a biotechnology company focused on developing treatments for age-related diseases. Founded in 2018 and based in San Francisco, California, the company aims to create a future where individuals live healthier for longer. It employs a transformative cellular model that mimics the complex characteristics of aging within a laboratory setting. By integrating this model with advanced artificial intelligence and computer vision, Fountain Therapeutics seeks to establish an innovative platform for identifying novel therapeutic targets. This approach is designed to facilitate the development of effective treatments for diseases associated with aging, ultimately aiming to reverse cellular aging and improve health outcomes.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Lightship is a company founded in 2018 that focuses on enhancing access, choice, and equity in clinical trials through decentralized and hybrid clinical services. By leveraging innovations in digital health and technology, Lightship aims to transform the clinical research landscape by improving patient experiences, retention, and trial diversity. The company moves beyond traditional research centers to make clinical studies more accessible, allowing medical research organizations to overcome the barriers and inefficiencies associated with conventional clinical trial models. Its mission centers on placing patients at the forefront, ensuring that clinical research is designed to meet the needs of diverse populations globally.

Connie Health is a provider of medical advisory services focused on enhancing the experience of older Americans in navigating Medicare decision-making. The company utilizes an AI-driven technology platform, complemented by local Medicare experts, to assist individuals in maximizing their insurance benefits, optimizing prescription costs, and identifying healthcare providers in their vicinity. By offering personalized support, Connie Health empowers seniors to make informed healthcare choices, select the most appropriate healthcare plans, and effectively understand the benefits of their insurance coverage.

Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, founded in 2016. The company specializes in developing rapid tests that assess the immune system to address significant clinical and public health challenges. Its primary focus is on creating diagnostics for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix employs proprietary machine-learning algorithms to analyze immune responses, producing clinically actionable results that support healthcare providers, particularly in emergency medicine, in making informed diagnostic decisions. Additionally, the company is building a diagnostics pipeline that includes tests for tropical infections, autoimmune diseases, transplant rejection, and various other conditions.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Digi-Prex is a Chronic disease management platform that provides patients with a holistic solution to assist in the management of their conditions. We start by providing these patients with a subscription that allows them access to discounted medicines delivered to their home regularly and provides them access to a full service platform customized to their particular condition allowing them a one stop shop to assist in the management of their condition.

Karma Biotechnologies, Inc. is a Los Angeles-based startup focused on developing therapies for autoimmune diseases, allergies, and food sensitivities. Founded in 2019, the company offers Xavines, a precision immunotherapy platform designed to address the critical need for antigen-specific therapies that target only the rogue immune cells responsible for these conditions. Unlike traditional treatments that rely on general immune suppression, Karma Biotechnologies aims to create tolerogenic immunotherapies that promote antigen-specific immune tolerance in vivo. By leveraging its expertise in immunology and lipid nanoparticle engineering, the company seeks to provide innovative solutions that enhance the treatment landscape for autoimmune diseases and related disorders.

Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics. It has dedicated experts focused on the investigation and advancement of next-generation therapies. It aims to help patients with chronic diseases, starting with Type 1 diabetes. It was founded in 2016 and is headquartered in San Francisco, California.

GEn1E Lifesciences Inc. is a biotechnology company based in Palo Alto, California, focused on developing innovative therapies for inflammatory and age-related diseases. Established in 2018, GEn1E employs a unique artificial intelligence platform to expedite the drug development process, targeting multiple mechanisms of action for protein therapeutics. Their portfolio includes MUC1-ED, an antibacterial therapy for pseudomonas infections, and a robust pipeline of over 21 novel immunomodulatory therapies aimed at rare diseases that currently lack effective treatments. The company’s AI-driven approach aims to significantly reduce the time and costs associated with drug development, with plans to advance additional therapies to investigational new drug (IND) status within the next year. GEn1E's team, comprised of experienced professionals in drug development and machine learning, is dedicated to creating life-saving treatments for patients in need, addressing the substantial unmet medical demands in the field.

Flow Neuroscience AB is a healthcare company based in Malmö, Sweden, focused on developing innovative treatment solutions for depression. Established in 2011, the company creates a wearable device that delivers transcranial direct current stimulation (tDCS) to the forehead, targeting the left frontal lobe, an area often associated with reduced activity in individuals suffering from major depressive disorder (MDD). This headset is complemented by a personalized mobile application designed to encourage users to adopt healthier daily routines, such as improved sleep patterns and increased physical activity. By combining brain stimulation with behavioral therapy, Flow Neuroscience aims to provide a medication-free treatment option that is accessible and affordable, challenging the traditional pharmaceutical approaches to depression. The company aspires to make these effective treatments widely available, moving beyond the confines of specialized clinics.

Bionaut Labs, Inc. is a biotechnology company based in Palo Alto, California, founded in 2016. The company specializes in developing a novel intra-tissue navigation platform utilizing Bionaut nano/micro robots that operate within the body. This innovative technology enables precise anatomical targeting for the treatment of central nervous system disorders, offering a new approach to precision medicine. By employing remote-controlled micro-robots, Bionaut Labs enhances the development of therapeutics, making advanced technologies like gene therapy and CRISPR-Cas9 feasible in challenging clinical scenarios. The Bionaut platform allows medical professionals to access any anatomic location within the body, facilitating the automation of complex procedures while eliminating the need for external incisions, thereby improving patient outcomes for those with limited treatment options.

Probably Genetic is dedicated to providing solutions for individuals with rare genetic conditions that are often misdiagnosed as autism spectrum disorder. Recognizing that patients typically endure a lengthy wait of up to seven years for a proper diagnosis, the company aims to alleviate this prolonged uncertainty. They offer educational resources and DNA sequencing tests designed to help individuals and families understand whether there is a genetic basis for their symptoms. By facilitating access to crucial information and testing, Probably Genetic seeks to support those who may otherwise be overlooked by the healthcare system.

Neurotrack is a digital health company focused on transforming the diagnosis and management of Alzheimer's and other dementias. Founded in 2012 by Elli Kaplan and neuroscientist Dr. Stuart Zola, the company is headquartered in Redwood City, California. Neurotrack develops user-friendly, clinically validated cognitive assessments that can be administered in clinical settings or at home, allowing for early detection of cognitive impairment and ongoing monitoring of cognitive function. The company's solutions are designed to fit seamlessly into various workflows, enabling healthcare providers to efficiently screen patients for cognitive decline and take necessary next steps. Neurotrack has published 27 peer-reviewed papers, holds 11 patents for its proprietary technology, and is registered as an FDA Class II medical device.

Sword Health is a digital health company focused on revolutionizing physical rehabilitation through its advanced artificial intelligence care platform. The company aims to alleviate pain for billions of people by providing a unique solution that combines the expertise of physical therapy professionals with an interactive AI experience. This platform enables patients to access customized rehabilitation exercises from their homes, allowing them to receive supervised care anytime and anywhere. Sword Health's approach not only enhances patient independence but also offers valuable data to clinical teams and decision-makers, ultimately improving clinical and cost-saving outcomes in the field of physical therapy.

Cellino is focused on creating an automated biomanufacturing system for personalized cell therapies, with the aim of making these treatments widely accessible. The company leverages an AI-guided laser editing platform that employs image-guided machine learning and robotics to generate autologous induced pluripotent stem cells (iPSCs) at scale. This innovative approach is designed to facilitate the development of potentially curative therapies for chronic degenerative diseases, such as vision loss and Parkinson's disease. By streamlining the process of cell therapy production, Cellino aims to enhance the availability of life-saving medicines for patients around the world.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

BioAge Labs, Inc. is a biotechnology company focused on developing therapies to address aging and age-related diseases. The company utilizes a systems biology and artificial intelligence platform to identify key drug targets that influence aging and analyze extensive datasets to uncover the molecular drivers of age-related conditions. BioAge Labs is advancing several drug candidates, including BGE-117, a hypoxia-inducible factor prolyl hydroxylase inhibitor designed to activate genes involved in critical biological processes such as tissue regeneration and vascular remodeling. Additionally, BGE-175, an orally administered inhibitor of the prostaglandin D2 DP1 signaling pathway, aims to mitigate risks associated with immune aging and respiratory infections. Founded in 2015 and based in Richmond, California, BioAge Labs is committed to discovering and developing innovative treatments that harness the biology of human aging.

CureSkin is a Bengaluru-based company founded in 2016 that specializes in AI-powered mobile applications for dermatological care. The app utilizes computer vision technology to analyze user-uploaded photos, identifying various skin issues such as acne, dark spots, scars, and pigmentation. Based on the analysis, CureSkin recommends personalized treatment plans, skincare products, and connects users with dermatologists for follow-up consultations. By offering these services, CureSkin aims to provide accessible and effective skin health solutions, particularly for individuals who may not have easy access to trained professionals.

Loop Genomics is a platform technology for long-read DNA sequencing. Loop Genomics technology transforms short-read DNA sequencers into high-throughput, long-read, single-molecule DNA sequencing machines. Loop Genomics long-read DNA sequencing technology provides phased sequencing solutions across a diverse repertoire of research and clinical applications. Sequencing of partial rRNA gene sequences results in reduced phylogenetic resolution. Full-length, high-throughput, phased sequencing that covers all 16S variable regions is becoming the gold standard for profiling the microbiome. Achieve the highest resolution microbial community profiling with long-read, next-generation sequencing of the microbiome. Characterizing polymorphisms in HLA genes inside and outside of the protein-coding regions is important for organ transplantation compatibility testing and for strengthening causality association studies. The length of homologous sequences between HLA alleles extends beyond the capabilities of short-read sequencing platforms, resulting in diploid ambiguities and a reliance on imputation. Sequence full-length HLA DNA and/or RNA with phased, high throughput, long-read sequencing that resolves allelic discrimination and diploid ambiguity. Viral genetic variability is a major determinant of viral drug resistance and viral vaccine efficacy. Accurately mapping viral genetic variability is a critical step in choosing the optimal course of therapy and developing efficacious vaccines. Key mutations are typically located throughout long stretches of viral genomes, making the retrieval of critical phased data challenging using short-read sequencing technology. Use phased, high-throughput DNA sequencing technology to map key mutations at the quasi-species level and generate a complete phased map of viral populations.

Remedy is a prescriptive chronic care analytics platform employing artificial intelligence to help value-based health systems determine who should get what care, when, how, and by whom to maximize patient health outcomes per dollar spent. We are a design-driven company with core medical AI technology capable of diagnosing disease, catching hidden high-risk diagnoses, and projecting the development of patient’s health into the future. Built around our core AI engine, our first product Remedy Sentinel helps value-based providers identify hidden chronic, co-morbid conditions and intervene by engaging high-risk patients prior to onset. We envision a world where healthcare marries the science of “health” with the art of “care”: scientific, data-driven decision making drives the best outcomes for each individual patient, and frees providers to focus on applying their human touch. Remedy combines novel artificial intelligence algorithms for predictive medical analytics with a healthcare-optimized product development process to give leaders the tools they need to transform their delivery networks and thrive in a value-based care environment. With this approach, Remedy builds a scalable suite of products that, when deployed, learn from experience, and grow into a solution optimized to fit the needs of specific provider groups and the populations they serve. Remedy systematically maximizes the patient health outcome achieved with each dollar spent by using AI to help determine what care is delivered to whom, when it is delivered, where it is delivered, how it is delivered, followed, and supported, and who should deliver it. We not only surface insights, but also build the necessary tools and helps coordinate step-by-step implementation processes to affect real change.

Lumiata Inc. specializes in predictive health analytics tailored for risk-bearing organizations, including hospital networks and insurance carriers. Founded in 2013 and based in San Mateo, California, the company has developed a medical graph that organizes and analyzes diverse healthcare data, enabling real-time predictive analytics. Its flagship product, The Lumiata Risk Matrix, provides personalized predictions regarding individual health changes, supported by a chain of medical reasoning. By leveraging over 120 million patient records and proprietary clinical knowledge, Lumiata's machine learning tools empower healthcare providers and payers to enhance decision-making, manage costs, and improve patient care. The company serves a range of clients, including payers, population health organizations, and digital health companies, facilitating applications in underwriting and care management while prioritizing member privacy.

Zebra Medical Vision Ltd. is a company that develops an imaging analytics platform aimed at enhancing patient care in healthcare institutions. Founded in 2014 and based in Shefayim, Israel, the platform utilizes advanced learning and computer vision algorithms to assist clinicians in identifying patients at risk of various diseases. This technology supports healthcare providers in implementing effective risk management and preventative care strategies. Zebra Medical Vision also supplies tools and datasets for machine-learning researchers, facilitating the rapid development of decision support tools and diagnostic solutions. The company has established strategic partnerships with organizations such as USARAD Holdings and TELUS Ventures, and has secured a total of $52 million in funding from notable investors, including Khosla Ventures and Nvidia. Its AI-driven products are FDA cleared and are utilized in hospitals across multiple regions, including the U.S., Europe, Australia, India, and Latin America, positioning Zebra Medical Vision as a leader in the field of medical imaging and analytics.

Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company leverages artificial intelligence to provide chat-based primary care services, aiming to make high-quality and affordable healthcare accessible to everyone, anytime. Curai Health's platform integrates clinicians with advanced AI and machine learning tools to create a learning healthcare system that enhances the efficiency and cost-effectiveness of medical care. By facilitating better communication between patients and healthcare professionals, the platform aids in accurate diagnosis and treatment. Curai Health offers its services directly to consumers and through partnerships with enterprises.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Neurotrack is a digital health company focused on transforming the diagnosis and management of Alzheimer's and other dementias. Founded in 2012 by Elli Kaplan and neuroscientist Dr. Stuart Zola, the company is headquartered in Redwood City, California. Neurotrack develops user-friendly, clinically validated cognitive assessments that can be administered in clinical settings or at home, allowing for early detection of cognitive impairment and ongoing monitoring of cognitive function. The company's solutions are designed to fit seamlessly into various workflows, enabling healthcare providers to efficiently screen patients for cognitive decline and take necessary next steps. Neurotrack has published 27 peer-reviewed papers, holds 11 patents for its proprietary technology, and is registered as an FDA Class II medical device.

Flow Neuroscience AB is a healthcare company based in Malmö, Sweden, focused on developing innovative treatment solutions for depression. Established in 2011, the company creates a wearable device that delivers transcranial direct current stimulation (tDCS) to the forehead, targeting the left frontal lobe, an area often associated with reduced activity in individuals suffering from major depressive disorder (MDD). This headset is complemented by a personalized mobile application designed to encourage users to adopt healthier daily routines, such as improved sleep patterns and increased physical activity. By combining brain stimulation with behavioral therapy, Flow Neuroscience aims to provide a medication-free treatment option that is accessible and affordable, challenging the traditional pharmaceutical approaches to depression. The company aspires to make these effective treatments widely available, moving beyond the confines of specialized clinics.

Q Bio, founded in 2015 by Jeffrey Kaditz, Dr. Michael Snyder, and Dr. Garry Choy, operates a clinical digital twin platform aimed at assessing patients' medical histories to identify immediate and future health risks. Based in San Carlos, California, the company utilizes whole-body scans to create a digital twin of each patient's physical body, quantifying and digitizing health data. By leveraging simulated human physiology and machine learning, Q Bio's platform can predict potential health risks, enabling healthcare professionals to provide proactive treatment. The interdisciplinary team at Q Bio comprises experts in applied mathematics, computational physics, electrical engineering, genetics, and radiology, supported by prominent venture capital firms.

Lumiata Inc. specializes in predictive health analytics tailored for risk-bearing organizations, including hospital networks and insurance carriers. Founded in 2013 and based in San Mateo, California, the company has developed a medical graph that organizes and analyzes diverse healthcare data, enabling real-time predictive analytics. Its flagship product, The Lumiata Risk Matrix, provides personalized predictions regarding individual health changes, supported by a chain of medical reasoning. By leveraging over 120 million patient records and proprietary clinical knowledge, Lumiata's machine learning tools empower healthcare providers and payers to enhance decision-making, manage costs, and improve patient care. The company serves a range of clients, including payers, population health organizations, and digital health companies, facilitating applications in underwriting and care management while prioritizing member privacy.

DocTalk Solutions India Private Limited, founded in 2016 and based in Mumbai, India, specializes in a mobile application that facilitates communication between patients and their doctors. The application allows users to chat with their doctors, obtain prescriptions, and share medical reports, making it easier for patients to manage their health without the need for in-person visits. By providing a convenient platform for consultations and medical advice, DocTalk enhances the patient experience and streamlines healthcare interactions.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.

MDalgorithms Inc. is a technology company based in Mountain View, California, founded in 2015. It specializes in developing applications for individuals dealing with acne and other skin disorders. By leveraging artificial intelligence and computer vision, MDalgorithms offers real-time mobile tools that allow users to conduct self-diagnosis and receive personalized treatment plans. The company’s applications analyze users' skin and scalp through selfies, delivering customized treatment kits directly to their homes. Additionally, clients benefit from chat support with a medical team, enhancing the accessibility and personalization of skincare and haircare regimes while shifting focus from traditional physician-centric models to a more patient-centered approach.

Guardant Health, Inc. is a precision oncology company based in Redwood City, California, specializing in blood tests, data analytics, and related services for cancer detection and treatment. The company is known for its innovative liquid biopsy tests designed for advanced-stage cancer, including Guardant360, which assesses multiple cancer-related genes, and GuardantOMNI, which offers a broader gene panel for immuno-oncology applications. Additionally, Guardant Health provides LUNAR-1, aimed at detecting minimal residual disease in cancer survivors, and is developing LUNAR-2 for early cancer detection in high-risk individuals. The company also supports biopharmaceutical firms and medical institutions with services such as companion diagnostic development, regulatory approval, and clinical trial referrals. Guardant Health has established collaborations, including one with Radius Health for developing a companion diagnostic related to elacestrant. Since its incorporation in 2011, the company has focused on advancing patient health through technological innovations in oncology.